NK cell therapy offers high safety and low side effects. It can be combined with other treatments to significantly enhance tumor therapy effectiveness.
More
Founded in 2022, Apexcella is a startup dedicated to NK cell therapy. The company has successfully transferred technology from Chang Gung Memorial Hospital and focuses on developing universal NK cell therapies.
Apexcella leverages its unique ApexNK® cell cultivation platform, cryopreservation technology, and super donor selection techniques to develop both autologous and allogeneic ApexNK® therapies, along with various CAR-NK immunotherapies. The company is dedicated to providing next-generation, innovative, low-side-effect, and broadly applicable cell therapies for multiple types of cancer, striving to develop diverse targeted cancer cell treatment solutions.
In Q1 2023, Apexcella successfully completed its angel round of funding, securing a $3.5 million investment. With comprehensive preclinical research data, the company plans to submit an IND application in 2024 and officially enter clinical trials.
